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ABSTRACT
Modern interventional radiology practice is continuously evolving. Developments
include increases in the number of central venous catheter placements and tumor treat-
ments (uterine fibroid therapy, radio- and chemoembolization of liver tumor, percutaneous
radiofrequency and cryoablation), and new procedures such as abdominal aortic aneurysm
stent-graft repair, vertebroplasty, kyphoplasty, and varicose vein therapies. There have also
been recent advancements in standard biliary and urinary drainage procedures, percuta-
neous gastrointestinal feeding tube placement, and transjugular intrahepatic portosystemic
shunts. Prophylactic antibiotics have become the standard of care in many departments,
with little clinical data to support its wide acceptance. The rise in antibiotic-resistant strains
of organisms in all hospitals worldwide have forced every department to question the use of
prophylactic antibiotics. The authors review the evidence behind use of prophylactic
antibiotics in standard interventional radiology procedures, as well as in newer procedures
that have only recently been incorporated into interventional radiology practice.
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Objectives: Upon completion of this article, the reader should be able to (1) state the correct timing of prophylactic antibiotic;
(2) determine which procedures benefit from prophylactic antibiotics; (3) explain the potential infectious complication for each
procedure; and (4) identify which patient groups are at increased risk for postprocedural infection.
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Prophylactic antibiotics (PR-ABXs) are widely
used in interventional radiology (IR), from simple
tunneled central venous catheter placement, to more
complex tumor therapy-related embolization. Many
interventional radiologists routinely give PR-ABXs,
though there is little evidence in the literature to
support this practice.
The routine and widespread use of broad-spec-
trum antibiotics has been responsible in part for the
emergence of more virulent antibiotic-resistant bacteria
in recent years,1 and the doubling of methicillin-resistant
Staphylococcus aureus (MRSA) infection rates in intensive
care units over the past 10 years.2 Not surprisingly, there
is a direct MRSA infection rate with the prophylactic use
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of third-generation cephalosporins.3 Likewise, the
percentage of enterococci resistant to vancomycin has
increased from 0.5% in 1989 to 25.9% in 1999.4
From physicians to hospitals to governments,
there has been more critical examination of PR-ABX
use and modification in clinical practice patterns.1,3,5
Multiday therapy has changed to single-dose PR-
ABX,6 and in some cases PR-ABX is altogether
eliminated.7 Critical examination of PR-ABX use in
IR must follow.
Surgical wounds are classified into four catego-
ries, each with a known infection risk. Clean wounds
(no gastrointestinal [GI], genitourinary [GU] or respi-
ratory tract access) carry an infection risk of <5%.
Clean-contaminated wounds (where the GI, biliary,
GU, or respiratory tract is entered without sign of
infection and no break of aseptic technique) carry a
10% infection risk. Contaminated wounds (presence of
infection or inflammation without pus) carry a 20%
infection risk, whereas dirty wounds (clinically infected
biliary or GU system or involving an abscess) carry a
39% infection risk.8 Spies and McDermott suggested
applying the wound classification to guide PR-ABX
use.8,9 PR-ABX use in IR has often been extrapolated
from surgical data, which may overestimate the risk
given smaller incisions with IR procedures.10 PR-ABX
use is generally accepted in clean-contaminated
wounds, and in clean procedures where prosthetic
material is implanted or where infection would be a
significant threat to the patient.11,12 Antibiotic use
prior to contaminated or dirty procedures is essential
but would be more correctly categorized as therapeutic,
not prophylactic. Specific at-risk groups will differ for
each type of procedure.8,13
Timing of PR-ABX is critical. Longer infusion
intravenous (IV) antibiotics may be given within
2 hours prior to incision,11 but short infusion IV anti-
biotic administration demonstrates greatest efficacy
when given within 30 minutes prior to incision.14
PR-ABX given after the surgical incision is less bene-
ficial.10 Direct correlation exists between the duration
of surgery and the risk of infection.6,13,15 In cases
lasting greater than 4 hours, redosing of the antibiotic
that was correctly given prior to surgery reduces the risk
of infection.14,16
Our goals are to identify the procedures that
would benefit from PR-ABX, identify the organisms
likely to be problematic for a specific procedure, identify
special patient groups most likely to be at risk for
procedure-related sepsis, and recommend the antibiotic
best suited for the procedure.
TUNNELED CENTRAL VENOUS CATHETER
Image-guided venous access procedures have low infec-
tion rates, even among patients who are immunocom-
promised. Catheter-related sepsis, or catheter-related
bloodstream infection (CRBSI), is most commonly
caused by coagulase-negative Staphylococci and Enter-
ococci. Fungal infections due to Candida are also relatively
common.
Infections are thought to be introduced through
hub manipulation rather than related to colonization of
the line at insertion. The infection risk for all central
venous catheters in the intensive care unit (ICU) is
estimated at 5.3 per 1000 catheter days.4 In the United
States, this results in 250,000 infections per year with a
12 to 25% mortality, at an average cost of $25,000 per
infection.
There is no difference in infection rates between
catheters placed in the operating room or IR suite,17
even in neutropenic patients.18 However, different in-
fection rates are reported depending on the device.
Totally implantable devices (ports) appear to have the
lowest infection rates (0.1–0.9 per 1000 catheter
days).19,20 Ports are more resistant to infection as there
is no external hub manipulation. In comparison, an
infection rate of 1.8 to 2.5 per 1000 days is seen with
Hickman catheters.20 Dialysis catheters have an infec-
tion rate of 4.2 per 1000 catheter days4 for cuffed
catheters and 7.1 per 1000 catheter days for noncuffed
catheters. Peripherally inserted central catheters (PICC)
have the highest rates of infection (up to 8 per 1000
catheters days in oncology patients).21
There is no evidence to support routine use of
PR-ABX prior to central venous catheter placement in
adults. This is largely based on a meta-analysis of nine
trials with 588 patients.27 A recent article did not
recommend routine antibiotic prophylaxis, but suggested
administering cefazolin (1 g IV) if placing a totally
implantable device or if the patient is immunocompro-
mised.22
Despite the existence of any conclusive evidence
supporting the use of PR-ABX, use of PR-ABX appears
to be standard practice among members of the Society of
Cardiovascular and Interventional Radiology (now the
Society of Interventional Radiology)23; cefazolin (1 g
IV) and vancomycin (1 g IV) have become standard of
care in penicillin allergic patients. The Centers for
Disease Control (CDC) discourages the use of prophy-
lactic vancomycin for catheter placement due to its use
increasing the risk of acquiring a vancomycin-resistant
Enterococci (VRE) infections.4
There are higher rates of infections in certain
subgroups, such as neutropenic and immunocompro-
mised patients, but there is no robust evidence to support
antibiotic use in theses populations. For example, higher
rates of infection were reported in HIV patients com-
pared with non-HIV patients in a prospective study of
391 patients, where all patients received PR-ABX.24
Similar infection rates are seen in neutropenic patients
as compared with those patients who are using their
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catheter for total parenteral nutrition (TPN)25 at the
time of placement.
The main preventative strategy is therefore pa-
tient education and appropriate postprocedure catheter
care. Also important are sterile technique, 2% chlorhex-
idine skin preparation, avoiding routine catheter
changes, hand-washing, hub sterility, minimal catheter
use, minimizing the number of lumens, and limiting
number of caregivers using the catheter.4,26 There is
some evidence that the high-risk patient may benefit
from flushing the catheter with antibiotic and heparin
solutions,27 locking the catheter with antibiotic solu-
tions, and using catheters impregnated with antimicro-
bial agents (chlorhexidine and silver sulfadiazine or
minocycline and rifampicin).28
VEIN SURGERY
Interventional radiologists are adding varicose vein pro-
cedures to their scope of practice. Endovenous thermal
ablations and phlebectomy procedures29 are being per-
formed, often in an outpatient procedure room. Endo-
venous laser ablation (EVLA) has a very low risk of
infection (0–0.1%) and requires no PR-ABX.30,31 There
is only a single case report of serious infection after
EVLA; the patient presented with infection on the fifth
postprocedure day, and required debridement and ex-
tensive local wound treatment.32 Ambulatory phlebec-
tomy also has a low risk of infection33,34 and PR-ABX
are also not recommended. No serious infective compli-
cations have been reported after isolated ambulatory
phlebectomy. A single case of necrotizing fasciitis was
reported after surgical stripping of the greater saphenous
vein and ambulatory phlebectomy performed with tu-
mescent anesthesia.
VERTEBROPLASTY AND KYPHOPLASTY
There are little data to support the routine use of PR-
ABX for vertebroplasty or kyphoplasty procedures.
There are only sporadic case reports of infection after
vertebroplasty or kyphoplasty and, indeed, no infections
were reported in a series of 1150 kyphoplasties after the
administration of 1.5 g of cefuroxime.35 However, given
the serious morbidity associated with bone or cement
implant infection, most operators choose to use PR-
ABX.
When infections do occur, the most common
bacteria are skin organisms such as Staphylococci and
Streptococci; therefore, 1 g cefazolin,22 1.5 g cefuroxime,35
or 600 mg clindamycin36 are recommended antibiotics.
Also of note, some operators use antibiotic-impregnated
cement in which 1.2 g of tobramycin is mixed with the
polymethyl methacrylate (PMMA) cement. There are
no reported advantages of intravenous antibiotics over
antibiotic-impregnated cement, or vice versa.
ARTERIOGRAPHY AND ENDOVASCULAR
STENT PLACEMENTS
Diagnostic angiography is considered a clean proce-
dure,37 although bacteremia has been reported to occur
in 4% of procedures. Transient bacteremia is seen in up
to 32% of patients undergoing angioplasty but there is no
associated increased risk of infection,9,38 although in one
study bacteremia was not seen in patients in the group
who received PR-ABX.38 Bacteremia is usually due to
skin flora.
Although uncommon, septic complications after
vascular procedures may be clinically significant. Septic
arteritis leading to pseudoaneurysm formation has been
reported after angioplasty and stent placement.39,40 Fac-
tors increasing infection risk include repuncturing the
same vessel, increased duration of stenting procedures,
the presence of hematoma, surgery in the area of recent
arterial access (<7 days), and immunosuppression.41,42
There is no robust evidence justifying PR-ABX for
routine percutaneous vascular interventions, but PR-
ABX may be of benefit when there is high risk of
infection.43
Prophylactic antibiotics are given routinely for
initial placement of endovascular aortic reconstruction
(EVAR); PR-ABX use is driven by fear of EVAR
infection, which is rare (0.43%) but carries a high risk
of mortality. Many patients (30%) undergoing EVAR
also require additional procedures, i.e., coil embolization
and treatment of endoleaks, which are significant risk
factors influencing the development of an infection.
Other risk factors include immunosuppression, treat-
ment of false aneurysms, and an infected central venous
catheter. Staphylococcus aureus has been isolated in over
one-half of the infections.44 Although there is no con-
clusive data to support use of PR-ABX, in this patient
population they may be indicated in patients undergoing
multiple procedures related to EVAR repair within a
short period.45 In patients undergoing EVAR and in
high-risk patients undergoing arterial intervention,
single-dose cefazolin 1 g intravenously at the time of
the procedure provides coverage against skin pathogens,
like Staphylococcus aureus and Staphylococcus epidermidis.
In patients allergic to penicillin, vancomycin is an alter-
native.22,46
ARTERIOVENOUS FISTULA AND GRAFT
INTERVENTIONS
In a retrospective study by Salman and Asif, the inci-
dence of clinical infection within 72 hours following
routinely performed percutaneous procedures for hemo-
dialysis access was 0.04%.47 This study included
2078 cases of percutaneous balloon angioplasty in both
arteriovenous (AV) grafts and fistulas, 106 cases of
thrombectomy of an arteriovenous fistula, 110 cases of
thrombectomy of an arteriovenous graft, 26 endovascular
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stent insertions, and 31 intravascular coil placements.47
Prophylactic antibiotics were not given in any of these
procedures. The study concluded that PR-ABX are
not necessary in routine interventional AV fistula-graft
related procedures.
ARTERIAL EMBOLIZATION FOR
GASTROINTESTINAL BLEEDING
AND HYPERSPLENISM
Prophylactic antibiotics are not routinely given in
patients undergoing embolization for posttraumatic or
gastrointestinal bleeding.46 Hemobilia is a rare situation
where PR-ABX may be indicated, where accumulation
of blood can lead to cholangitis from biliary obstruction.
In this situation, PR-ABX recommended for biliary
drainage procedures may be advisable.
In patients undergoing selective or partial splenic
artery embolization for trauma or hypersplenism, PR-
ABX are recommended.48,49 The risk of splenic abscess
and bacterial peritonitis increases when greater than 70%
of total splenic volume is embolized; there is a 16% risk
of infection with >70% of the spleen embolized com-
pared with a 3% risk when 50 to 70% is embolized.50
One recommend antibiotic regimen is the administra-
tion of 1 g of cefoperazone every 12 hours postprocedure
for at least 5 days following the embolization proce-
dure.49 An alternative is to use embolic particles sus-
pended in gentamicin (16 mg) in combination with a
5-day course of IV amoxicillin-clavulanate (3 g/day) and
ofloxacin (400 mg/day).50
UTERINE EMBOLIZATION
Over 100,000 women worldwide have undergone embo-
lization of the uterine arteries for treatment of fibroids51
since Ravina et al published their original experiences.52
Prophylactic antibiotic regimens have evolved from
multiple-day, multidrug therapy to a single medication
administered prior to the procedure. Some practitioners
advocate using no PR-ABX at all.
Infectious complications include endometritis,
leiomyoma infection, and myometrial infection secon-
dary to uterine necrosis.53Escherichia coli (E. coli) is the
most common pathogen.54–56
Early regimens involving multiday and multidrug
therapy resulted in a high percentage (16.7%) of patients
returning to the hospital with an infection. In addition,
2.4% of these patients ultimately required hysterec-
tomy.55 In one study, multidrug therapy given once prior
to procedure resulted in lower rates of infection (2%),
with only 0.8% of these cases leading to hysterectomy.
However, vaginal discharge resulting from endometritis
was seen in up to 58%, suggesting that aggressive PR-
ABX led to imbalance of bacterial flora allowing the
gram-negative bacteria to flourish.54,57 More recent case
series in the literature reflect a trend toward single dose
of prophylaxis or no PR-ABX. A single dose of 1 g of
cefazolin or 1 g of vancomycin are commonly used
regimens.58,59
Two cases of death from sepsis postuterine em-
bolization are reported in the literature56,60; overembo-
lization and uterine necrosis are believed to be the
inciting factors leading to infection, septic shock, diffuse
intravascular coagulation (DIC), multiple organ failure,
and ensuing death in the second patient.61 In another
series, 5.9% of patients presented with minor infection
and 2.6% of patients presented with septicemia requiring
emergent myomectomy or hysterectomy.62
The risk of infection is increased with aggressive
multiple-day antibiotic therapy,57 overembolization (de-
velopment of uterine necrosis),60 and vaginal passage of
sloughed fibroid material (possible ascending infection),
which can occur in up to 7.7% of patients.62 Studies that
separated the infectious complications by patients who
did and did not receive PR-ABX failed to show stat-
istical significance between the two groups.55,58
The Royal College of Obstetricians and Gynae-
cologists state that there is insufficient data to recom-
mend PR-ABX in patients undergoing uterine artery
embolization.51 If used, the current antibiotic of choice
for prophylaxis, is a first-generation cephalosporin
(cephazolin 1 g) or vancomycin (500–1000 mg IV).45
Patients who are at high risk for pelvic infection may
benefit from clindamycin (900 mg IV) and gentamicin
(80 mg IV), which cover Neisseria gonorrhoeae, Chlamy-
dia trachomatis, and anaerobic bacteria.53
VENOUS EMBOLIZATION
Varicocele embolization has very low complication rates
and routine PR-ABX is not recommended.22 Patients
undergoing percutaneous sclerotherapy for vascular mal-
formations, however, may benefit from a single dose of
cefazolin (1 g IV) or vancomycin (1 g IV) prior to
procedure.
TRANSJUGULAR INTRAHEPATIC
PORTOSYSTEMIC SHUNT (TIPS)
Up to 10% of patients develop fever post-TIPS despite
the use of PR-ABX. Whether the fever is secondary to
actual infection of the TIPS (endotipsitis) or TIPS-
induced bacteremia is unclear.63
Endotipsitis occurs in up to 1% of cases and is
diagnosed when a febrile patient post-TIPS has positive
blood cultures and thrombus or vegetation on the stent
on imaging studies.64,65 It is often a diagnosis of ex-
clusion in a post-TIPS patient with persistent bacter-
emia and no other source of infection.66 Patients with
endotipsitis generally respond well to antibiotic treat-
ment.63,66 A broad spectrum of organisms including
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fungi have been attributed to endotipsitis.65 A random-
ized trial comparing no PR-ABX to single dose prophy-
laxis using 2 g cefotiam failed to demonstrate a
significant difference in postprocedural infection.67 At
this time, PR-ABX is not recommended for routine
TIPS patients.
In patients where difficulty in placement of the
TIPS is anticipated, i.e., patients with partial thrombosis
of portal vein, elevation of the right hemidiaphragm, or
in difficult TIPS cases lasting several hours in duration,
PR-ABX may be of greater value. In these instances, a
single dose of cefazolin or ceftriaxone are two antibiotics
that some practitioners use.22
PERCUTANEOUS TUMOR ABLATIONS
Within recent years, image-guided thermal ablation of
localized tumor has become a viable treatment option for
many patients. Ablation techniques include radiofre-
quency (RFA), microwave, laser, ultrasound, and cryoa-
blation.68 The use of these techniques has been
extensively studied in liver tumors and their application
is expanding into malignant lung, renal, and adrenal
tumors as well as benign bone tumors.
Less than 1% of liver ablations result in infectious
complications, the majority of which are hepatic abscess
formation.69–72 A study by Shibata et al found no
statistically significant difference in infection rates be-
tween patients who did or did not receive PR-ABX.72
The mechanism of infection posttumor ablation is not
well understood, but may result from contamination of
necrotic tissue. A bilioenteric communication may place
the patient at increased risk for postablation abscess
formation.70 In addition, in a multicenter study by
Livraghi et al the presence of a biloenteric anastomosis
was a statistically significant risk factor for patients who
developed infection postablation71 In the same study,
diabetic patients were also noted to be at high risk for
developing infectious complications following hepatic
ablation.71 Similar risk factors are suggested in patients
undergoing RFA of renal cell carcinoma. A case report
of two patients with an ileal conduit who developed
infectious complications despite receiving PR-ABX,
suggests a similar mechanism of infection via coloniza-
tion of the genitourinary tract.73
Mixed flora are seen in liver abscesses following
ablation or embolization. In the single reported case of
liver abscess following ethanol ablation, E. coli, Clostri-
dium perfringens, and Enterococcus were isolated74
There are no randomized control trials to support
the routine use of PR-ABX, but many operators use PR-
ABX.70–72 There is, however, empiric support for use
of PR-ABX in high-risk patients who have previous
bilioenteric anastomosis, biliary stasis/ductal dilation,
severe cirrhosis, immunosuppression, diabetes, and con-
comitant infection.68
Single-dose or a short (few days) course of anti-
biotics may be effective in patients with sterile biliary
systems. A single dose of ampicillin/sulbactam (1.5–3 g
IV)22,46 is recommended. However, with chronic bili-
ary bacterial colonization as seen in bilioenteric anas-
tomosis, or recent colonization following a biliary
intervention procedure, a prolonged period of prophy-
laxis may be required to sterilize the biliary tract and
prevent abscess formation. Multiday prophylaxis of
cephazolin or cefmetazole (1 g IV) one day before
ablation and every 12 hours until discharge,72 or amox-
icillin/clavulanate (Augmentin1 2 g IV; GlaxoS-
mithKline, Brentford, London, UK) immediately
before the procedure and continued daily for 2 to
3 days74 are two recommended regimens. Similar
PR-ABX can be applied to ablation involving kidney,
lung, and bone depending on clinical presentation.
LIVER TUMOR EMBOLIZATION
Catheter-directed embolization is currently a first-line
treatment for unresectable hepatic tumors. Types of
embolization include bland embolization, transarterial
chemoembolization (TACE), and radioembolization
(Yttrium-90 [Y-90] microspheres). An infected focus
of tumor necrosis can lead to liver abscess, cholangitis, or
frank sepsis.
TACE has been shown to have a very low rate of
liver abscess formation. In two separate studies, three
abscesses were seen in a series of 1348 cases,75 and seven
abscesses (one splenic and six hepatic) were seen in
another series of 827 TACE sessions.76 Patients who
developed complications had risk factors including major
portal vein obstruction, intrahepatic biliary obstruction,
bilomas, ascites, and previous Whipple operation.77
Patients with metastatic disease from a gastrointestinal
primary exhibit a greater risk of infection after TACE,
compared with primary liver tumors (7% vs 0.8%),
respectively. This is thought to be due to preexisting
compromise of bowel mucosal integrity by malignant
ulcerative lesions.78
The incidence of liver abscess following radio-
embolization is also uncommon. In one study, only two
cases of liver abscesses were seen in a series of 327
patients undergoing Y-90 radioembolizations.79 In a
review by Salem and Thurston on Y-90 radioemboliza-
tion, it was concluded that apart from mild postembo-
lization symptoms, most complications are due to
nontarget embolization that can result in radiation-
induced inflammation of the pancreas, lung, gallbladder,
liver, and bowel.81 For radioembolization, PR-ABX are
not routinely recommended unless the patient presents
with risk factor for infection, such as prior biliary
surgery, diabetes, portal vein thrombosis, biliary obstruc-
tion, or gallstones. One antibiotic regime includes am-
picillin-sulbactam (3 g IV) and vancomycin (1 g IV)
PROPHYLACTIC ANTIBIOTIC GUIDELINES/MOON ET AL 331
prior to the radioembolization procedure and during
overnight hospitalization, and Augmentin1 (875 mg
orally every 12 hours for 5 days after discharge home).
Ampicillin-sulbactam can be replaced with IV and oral
ciprofloxacin in penicillin-allergic patients.
Infection from gas-forming anaerobes are com-
mon,77,80,82 and the most frequent pathogen causing
the liver abscess is Klebsiella pneumoniae.83 PR-ABX
regimes include broad-spectrum and anaerobic IV
antibiotic coverage, such as IV cefazolin and metroni-
dazole, prior to and during the hospitalization post-
TACE, followed by a 5-day course of broad-spectrum
oral antibiotics (Augmentin1 or ciprofloxacin).84
Routine bowel preparation is also advocated by some
operators.
PERCUTAENOUS GI TUBE PLACEMENT
Gastrostomy (G), gastrojejunostomy (GJ), and jejunos-
tomy (J) tubes can be placed percutaneously.85,86 Radio-
logically placed catheters had lower risks for major
infection, septicemia, and wound dehiscence when com-
pared with endoscopically placed catheters (0.8% vs
3.3%, respectively).87 There is a 3% risk of developing
subcutaneous abscess and septicemia and 25% risk
of minor infection in patients who did not receive
PR-ABX.88 Peristomal infection rates are reported to
be as high as 38% following placement of G tubes
with radiologic guidance in children, despite the use of
PR-ABX.89
De novo placement of J tubes under fluoroscopic
guidance is also becoming more common.90,91 Local
tube site infections associated with image-guided place-
ment are usually polymicrobial and include Staphylococcus
aureus, b-hemolytic Streptococci, and fungi.85
There is evidence that PR-ABX reduces infec-
tious complication after endoscopic placement of G and
GJ tubes, with fewer infections seen in those who
received PR-ABX.92–94 However, with the very low
risk of readily treatable superficial infection, routine
use of PR-ABX is difficult to justify. PR-ABX is
recommended for patients at high risk for infection,
such as malnourished pediatric patients and the immu-
nocompromised. A single dose of cefazolin (1 g IV
30 minutes to 1 hour prior to the procedure),93 or a
5-day regime of cefazolin (1 g IV) and cephalexin
(500 mg twice daily [bid] orally or via gastrostomy) are
reported. Clindamycin (600 mg IV and 600 mg bid
orally or via gastrostomy for 5 days) can be substituted.94
BILIARY INTERVENTIONS
Biliary interventions encompass interventions where
access to and drainage of bile are performed,
either through the bile ducts directly or through the
gallbladder.
Infective cholangitis (infection of the bile ducts),
often involves retrograde ascent of organisms from
the duodenum or from portal venous seeding. When
colonization of a normally sterile biliary system occurs
along with obstruction of its outflow, the increased
pressure in the biliary system can ‘‘intravasate’’ organisms
into the blood steam, resulting in sepsis.95
Enterococcus, E. coli, Klebsiella, and yeast are com-
monly encountered pathogens in the setting of cholan-
gitis.95,96 De novo access into the biliary system results in
biliary systems that are 60% positive for organisms, but
rises to 85% at 24 hours postprocedure, and to virtually
100% during exchange of the catheters. This suggests
secondary colonization through catheter placement.97
The use of PR-ABX can also change the biliary flora
in patients undergoing multiple biliary procedures. A
second biliary procedure (up to 7 days after the first) may
carry increased risk for sepsis due to selective eradication
of other organisms sensitive to the original PR-ABX.98
Randomized-controlled trials of PR-ABX prior
to endoscopic retrograde cholangiopancreatography
(ERCP) demonstrate no significant effect of PR-ABX,
and therefore routine use is not recommended.99 Like-
wise, the American Society for Gastrointestinal Endos-
copy does not recommend routine use of PR-ABX
performed for biliary obstruction in the absence of
cholangitis and where complete drainage is anticipated.
If incomplete drainage is anticipated, as in hilar stric-
tures or primary sclerosing cholangitis, PR-ABX are
recommended. The Society of Interventional Radiology,
on the other hand, recommends PR-ABX in all patients
undergoing percutaneous transhepatic biliary drainage
(PTBD) procedures because there is an anticipated rate
of sepsis of 2.5%.100
The question of whether or not to use PR-ABX
usually arises in the setting of patients with no signs or
symptoms of biliary sepsis prior to biliary access proce-
dures. The use of antibiotics prior to percutaneous
transhepatic cholangiogram should be considered on a
case-by-case basis based on the risk factors and expected
findings. Prophylactic antibiotics are recommended
where inadequate or incomplete drainage is anticipated
(hilar strictures, primary sclerosing cholangitis, biliary
stones) or if the patient had a recent ERCP or PTBD
(e.g., less than a week). Due to the anticipated coloni-
zation of the biliary catheter, PR-ABX are also recom-
mended for routine catheter exchanges. Patients who are
clinically septic should be treated with appropriate anti-
biotic therapy prior to the proposed procedure, and
hence require no prophylaxis.
Piperacillin demonstrates good biliary excretion
and coverage of the biliary bacterial flora101 with de-
creased risk of nephrotoxicity. It is currently used more
often in combination with tazobactam, which counters
b-lactamase producing species of E. coli (Zosyn1
3.375 g IV; Wyeth Pharmaceuticals, Collegeville, PA).
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Alternatives would be third-generation cephalosporins
(ceftriaxone 1 g IV),22 or ampicillin/sulbactam (1.5–3 g
IV).46
PERCUTANEOUS NEPHROSTOMY
The use of PR-ABX in percutaneous nephrostomy
(PCN) is directed toward preventing urosepsis from
intravasation of organisms into the bloodstream occur-
ring from manipulation of the infected urinary system.22
Percutaneous nephrostomy tubes can be categorized
from clean-contaminated (sterile hydronephrosis), to
contaminated (in presence of infected stone disease), to
dirty (in the presence of urosepsis or pyonephrosis), and
the choice of PR-ABX therefore differs from true
prophylaxis to treatment.8,46 Even with appropriate
PR-ABX, the rate of sepsis in PCN is as high as 2.2%,
and as high as 7 to 9% in patients presenting with
pyonephrosis.23
E. coli, Klebsiella, Proteus, and Enterococcus com-
monly cause urinary sepsis.102 However, in patients
with struvite stone disease, urease-producing bacteria,
such as Staphyloccocus aureus, Staphylococcus epidermidis,
Pseudomonas aeruginosa, Micrococcus luteus, and especially
Proteus mirabilis may be found; it is noted that the
bacteriology of the stone may not be reflected in urine
culture.103
Patients who are at high risk for infectious com-
plications include the elderly and those who are immu-
nosuppressed, as well as patients with diabetes, stone
disease, ureterointestinal conduits, renal insufficiency
or voiding dysfunction, and previously instrumented
patients who are suboptimally drained.104
The use of PR-ABX is not universally accepted in
PCN. Some feel that PR-ABX is not indicated for use in
routine PCN,105,106 whereas others give multiday third-
generation cephalosporins and gentamicin to all patients
undergoing PCN.107 For standard PCN in low-risk
individuals, recommendations range from no PR-ABX
to first-generation cephalosporins.46,106 For patients at
high risk for infection including those patients with
calculi, broader coverage with ceftriaxone, ampicillin-
sulbactam, ampicillin and gentamicin, or cephalosporin
and gentamicin is recommended.22,46,106 Although the
choice of PR-ABX is important, it is as important to
exercise good technique in performing PCN to prevent
sepsis; overdistension of the renal collecting system
or overmanipulation of an infected system can force
bacteria into the blood system and cause sepsis.46,108,109
Other urinary tract procedures, such as suprapubic
cystostomy, also have a relatively high rate (9%) of
postprocedural sepsis.110 A two-tiered antibiotic ap-
proach may be used in these patients. A one-time dose
of a first-generation cephalosporin or single-dose
gentamicin is appropriate for uncomplicated patients.
Ampicillin-sulbactam, ampicillin with gentamicin, or a
cephalosporin with gentamicin is recommended for
high-risk patients or patients presenting with signs of
infection.
Up to 17% of patients may present with bacter-
emia during nephrostomy catheter exchange,111 regard-
less of periprocedural antibiotics. In patients who are
undergoing a routine nephrostomy tube change, there is
a lower risk of sepsis, and similar antibiotic prophylaxis
that is used for low-risk percutaneous nephrostomy
procedures can be used in these patients. Although there
are practitioners who opt not to give a prophylactic
antibiotic for routine catheter exchanges, there are sit-
uations where IV infusion of antibiotic may be invalu-
able (e.g., catheter malposition or malfunction).
FALLOPIAN TUBE RECANALIZATION
The use of PR-ABX is not universally recommended for
fallopian tube recanalization.112 If used, a 5-day course
of doxycycline (100 mg orally twice daily, started 2 days
prior to procedure), or doxycycline (200 mg orally
immediately before the procedure followed by 100 mg
orally twice daily for 5 days) are two regimens in the
literature to prevent peritonitis postprocedure.112–114
Ancef (1 g IV) or vancomycin (1 g IV) in patients
with penicillin sensitivity are also alternatives.
NONINFECTED DRAINAGE PROCEDURES
AND BIOPSY
There is no evidence to support the use of PR-ABX for
percutaneous biopsy or drainage of noninfectious lesions
such as lymphoceles or renal cysts.
Transrectal prostatic biopsy is the only biopsy
procedure in which PR-ABX are currently recom-
mended. Infectious complications include prostatitis
and even Fournier gangrene. Based on a retrospective
review of a series of 1018 TRUS biopsies, higher
infections rates have been reported if no antibiotics are
administered115 Different complex regimes such as in-
tramuscular gentamicin (80 mg 30 minutes before the
procedure), and a 5-day course of ciprofloxacin (250 mg
orally bid) have been reported.8 A recent randomized
study of 363 patients demonstrated no difference be-
tween an oral agent given once compared with a 3-day
course.116 Also, no difference was seen in a randomized
study of 300 patients given either a single dose of
fluoroquinolone before or after the procedure.117
Although there is evidence to support the routine use
of PR-ABX for transrectal prostatic biopsies, the actual
antibiotic regime and timing do not appear to be critical.
ABSCESS DRAINAGE
Patients referred for percutaneous intraabdominal abscess
drainage are almost invariably already being treated with
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antibiotics; if the patient is not yet on antibiotics, ini-
tiation of treatment is recommended prior to drainage.8,9
CONCLUSION
Though there is largely a lack of robust data to support
routine PR-ABX for most interventional procedures,
there is a role for PR-ABX in several situations as
described. For each procedure, it is important to under-
stand the risk of infectious complications and the ration-
ale for PR-ABX. Where the role for PR-ABX is
debatable, or where there are several suggested regimes,
we suggest that well-designed randomized controlled
trials be conducted.
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